PACB — Pacific Biosciences Of California Income Statement
0.000.00%
Last trade - 00:00- $555.51m
- $902.01m
- $154.01m
Annual income statement for Pacific Biosciences Of California, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | PRESS |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 131 | 128 | 201 | 154 | 160 |
| Cost of Revenue | |||||
| Gross Profit | 58.9 | 52.7 | 56.2 | 38.3 | 50 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 393 | 436 | 537 | 474 | 714 |
| Operating Profit | -262 | -307 | -337 | -320 | -554 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -275 | -314 | -318 | -310 | -546 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -181 | -314 | -307 | -310 | -546 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -181 | -314 | -307 | -310 | -546 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -181 | -314 | -307 | -310 | -546 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.623 | -1.38 | -1.17 | -0.996 | -0.92 |